Abstracts tagged "Biologicals"

Abstract Number: 1980 • ACR Convergence 2022
Seroconversion After a Third COVID-19 Vaccination in Rheumatoid Arthritis Patients Treated with (ultra-)low Dose Rituximab with a Previous Insufficient Humoral Response Is Associated with Rituximab Dosage
Céleste van der Togt¹, David Ten Cate¹, Janette Rahamat-Langendoen², Bart van den Bemt³, Nathan den Broeder⁴ and Alfons den Broeder⁴, ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²ErasmusMC, Rotterdam, Zuid-Holland, Netherlands, ³Department of Pharmacy, Sint Maartenskliniek, Ubbergen, Netherlands, ⁴Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Around 60% of rheumatoid arthritis (RA) patients treated with ≥1000 mg rituximab (RTX) has an insufficient deemed humoral response after two COVID-19 vaccinations. Recent…
Abstract Number: 2129 • ACR Convergence 2022
Serum Extracellular Matrix Biomarkers Identify Response to Guselkumab in Psoriatic Arthritis; Post-hoc Analysis from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
Signe Holm Nielsen¹, Anne-Christine Bay-Jensen¹, Peder Frederiksen¹, Morten Karsdal¹, May Shawi², Soumya Chakravarty³, Alexa Kollmeier⁴, Warner Chen⁵ and Sheng Gao⁵, ¹Nordic Bioscience, Herlev, Denmark, ²Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ³Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁴Janssen-Cilag, Research & Development, LLC, San Diego, CA, ⁵Janssen Research and Development, LLC, Spring House, PA
Background/Purpose: Psoriatic arthritis (PsA) is a progressive, joint-degenerative inflammatory disease with cartilage destruction, bone erosion and growth, and synovitis. Extracellular matrix (ECM) remodeling is also…
Abstract Number: 2259 • ACR Convergence 2022
Complete Resolution of Inflammation on MRI Is Associated with a Better Clinical Response over Time in Patients with Early Axial Spondyloarthritis
valeria Rios-Rodriguez¹, Murat Torgutalp², Christian Althoff³, Hildrun Haibel², Kay-Geert Hermann², Fabian Proft⁴, Mikhail Protopopov⁵, Judith Rademacher⁵, Joachim Sieper² and Denis Poddubnyy⁴, ¹Charité-Universitätsmedizin Berlin, Berlin, Germany, ²Charité - Universitätsmedizin, Berlin, Berlin, Germany, ³Helios Klinikum Emil von Behring, Berlin, Germany, ⁴Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁵Charité Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Magnetic resonance imaging (MRI) of the spine and sacroiliac joints (SIJ) are important tools for the diagnosis of axial SpA and the presence of…
Abstract Number: 0199 • ACR Convergence 2022
Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes – 16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis
Peter Taylor¹, Frank Behrens², Philip J Mease³, Dieter Wetzel⁴, Paul Peloso⁵, Nicolai Brun⁴, Brian Wiens⁶, Jan Brandt-Juergens⁷, Edit Drescher⁸, Eva Dokoupilova⁹, Anna Rowińska-Osuch¹⁰, Nadia Abdel- Kader Martin¹¹ and Kurt de Vlam¹², ¹University of Oxford, Oxford, United Kingdom, ²Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁴Affibody AB, Solna, Sweden, ⁵ACELYRIN, Naples, FL, ⁶ACELYRIN, Inc., Los Angeles, CA, ⁷Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁸Veszprem Megyei Csolnoky Ferenc Korhaz, Budapest, Hungary, ⁹Medical Plus, s.r.o. & Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Brno, Prague, Czech Republic, ¹⁰ETG Network - Rheumatology, Warsaw, Poland, ¹¹Hospital Infanta Luisa Quiron, Rheumatology, Sevilla, Spain, ¹²University Hospitals Leuven, Leuven, Belgium
Background/Purpose: Izokibep is a unique IL-17A inhibitor with high potency and small molecular size designed to overcome the limitations of monoclonal antibodies. IL-17 is a…
Abstract Number: 0348 • ACR Convergence 2022
Significant Improvement in Cutaneous Lupus Erythematosus with or Without Systemic Lupus Erythematosus with Belimumab Use – a Systematic Review and Meta-Analysis
Rachel Kneeland¹, Daniel Montes¹, Justin endo¹, Bridget Shields¹, Christie Bartels² and Shivani Garg³, ¹University of Wisconsin, School of Medicine and Public Health, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI, ³University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Cutaneous lupus erythematosus (CLE) with or without systemic lupus erythematosus (SLE), can be debilitating and cause significant scarring and psychological distress. Belimumab, a monoclonal…
Abstract Number: 0430 • ACR Convergence 2022
The Course of Bone Mineral Density During 8 Years of Treatment with TNF-α Inhibitors in Patients with Ankylosing Spondylitis
Mark Siderius¹, Anneke Spoorenberg², Freke Wink³ and Suzanne Arends², ¹University Medical Centre Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³Medical Center Leeuwarden, Leeuwarden, Netherlands
Background/Purpose: Bone loss reflected by lower bone mineral density (BMD) compared to age and gender matched healthy controls is a common feature of ankylosing spondylitis…
Abstract Number: 0771 • ACR Convergence 2022
The Use of a bDMARD or tsDMARD for the Management of Rheumatic irAE Under Checkpoint Inhibitors: An Observational Study
Fanny De La Fuente¹, Rakiba Belkhir², Julien Henry³, Chi Duc Nguyen⁴, Thao Pham⁵, Vincent GERMAIN⁶, Pierre-Edouard Gavand⁷, Céline Labadie¹, Claire Brière⁸, Ambre Lauret⁸, Thierry Cardon⁹, Gaël Mouterde¹⁰, Isabelle Bonnet¹¹, Léa Rouxel¹², Marie Truchetet¹, Thierry schaeverbeke¹³, Christophe Richez¹⁴ and Marie Kostine¹⁵, ¹Bordeaux University Hospital, Bordeaux, France, ²Rheumatology departement, Bicêtre, Paris-Saclay university, Le Kremlin Bicêtre, France, ³Department of Rheumatology, University Paris-Saclay, Hospital Bicêtre, Le Plessis Robinson, Ile-de-France, France, ⁴Bethune Hospital, Bethune, France, ⁵Aix-Marseille univ, APHM, Marseille, France, ⁶Pau Hospital, Rheumatology, Pau, France, Pau, France, ⁷Rhena Clinic, Strasbourg, France, ⁸Intercommunal Creteil Hospital, Créteil, France, ⁹Lille University Hospital, Lille, France, ¹⁰Lapeyronie Hospital, Montpellier, France, ¹¹University Paris-Saclay, Hospital Bicêtre, Bicêtre, France, ¹²Arcachon Hospital, Arcachon, France, ¹³CHU de Bordeaux, Bordeaux, France, ¹⁴Université de Bordeaux, Bordeaux, France, ¹⁵Pellegrin Hospital, University Hospital of Bordeaux, Rheumatology, Bordeaux, France
Background/Purpose: Rheumatic immune related adverse events (irAEs) are observed in about 5 to 10% of cancer patients receiving checkpoint inhibitors (ICIs), with inflammatory arthritis (IA)…
Abstract Number: 0887 • ACR Convergence 2022
Comparison of Drug Persistence and Incidence of Tuberculosis Between Tumor Necrosis Factor-α Inhibitors and Tocilizumab as the First-line Biological Treatment in Patients with Rheumatoid Arthritis Using the Korean Health Insurance Review and Assessment Service Database
Byung Wook Song, Dong-Hyuk Moon, Aran Kim and Seung-Geun Lee, Division of Rheumatology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea
Background/Purpose: Drug persistence represents long-term therapeutic performance in real clinical setting and tuberculosis (TB) is one of the most important adverse events following biological treatments…
Abstract Number: 1040 • ACR Convergence 2022
Impact of Weight and Sex on Long-term Persistence to Secukinumab Treatment in Patients with Active Psoriatic Arthritis or Ankylosing Spondylitis
Uta Kiltz¹, Petros P. Sfikakis², Nicola Gullick³, ATHINA THEODORIDOU⁴, Anna Kandyli⁵, Jan Brandt-Juergens⁶, Philippe Goupille⁷, Nicola Maiden⁸, Karl Gaffney⁹, Daniel Peterlik¹⁰, Barbara Schulz¹¹, Effie Pournara¹¹ and Piotr Jagiello¹¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, ³University Hospital Coventry & Warwickshire; Warwick Medical School, University of Warwick, Coventry, United Kingdom, ⁴Euromedica Geniki Kliniki, General Hospital, Thessaloniki, Greece, ⁵Rheumatology Outpatient Clinic, Iaso General Hospital, Athens, Greece, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Rheumatology department, University Hospital of Tours, Tours, France, ⁸Craigavon Area Hospital, Southern Health & Social Care Trust, Craigavon, United Kingdom, ⁹Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, ¹⁰Novartis Pharma GmbH, Nürnberg, Germany, ¹¹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC) has demonstrated a high sustained response rate in patients (pts) with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) across Phase III clinical…
Abstract Number: 1403 • ACR Convergence 2022
Herpes Zoster in Rheumatoid Arthritis: Prospective Single University Center Study
Lucia Cristina Dominguez Casas¹, Mª Paz Rodriguez Cundin², Trinidad Dierssen Sotos³, Nuria Vegas Revenga⁴, Alfonso Corrales⁵, Miguel Ángel González-Gay⁶ and Ricardo Blanco⁷, ¹Hospital Universtario San Agustin, Oviedo, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Universidad de Cantabria, Santander, Spain, ⁴Hospital Galdakao- Usansolo, Galdakao, Spain, ⁵Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Patients with Rheumatoid arthritis (RA) have an increased risk of infections due to the disease itself, and/or immunosuppressive therapy. The risk of herpes zoster…
Abstract Number: 1558 • ACR Convergence 2022
Prevalence, Phenotypical Clinical Clusters and Treatment of Neurobehçet’s Disease: Study in Northern Spain
Alba Herrero-Morant¹, Carmen Alvarez Reguera², Lara Sánchez-Bilbao², David Martínez-López², guillermo Suárez-Amorin², Raúl fernández-ramón², José Luis Martín-Varillas³, Cristina Mata⁴, Miguel Ángel González-Gay⁵ and Ricardo Blanco⁶, ¹Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital de Laredo, Laredo, Cantabria, Spain, ⁴Hospital Laredo, Santander, Spain, ⁵Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Behçet's disease (BD) may present with different clinical phenotypes. Ocular and Neurobehçet's Disease (NBD) are severe complications. Data on NBD epidemiology, clinical phenotype and…
Abstract Number: 1994 • ACR Convergence 2022
Is Glucocorticoid Bridging Associated with Later Glucocorticoid and Biological DMARD Use in Patients with Rheumatoid Arthritis?
Lotte van Ouwerkerk¹, Sytske Anne Bergstra², Tjardo Maarseveen¹, Rachel Knevel¹, Tom Huizinga¹ and CF Allaart¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Netherlands
Background/Purpose: Glucocorticoids (GC) are rapidly effective in suppressing disease activity in rheumatoid arthritis (RA), and are often used as 'bridging' therapy while slower acting conventional…
Abstract Number: 2131 • ACR Convergence 2022
Minimal Disease Activity Response Patterns in Bio-Naïve Patients Treated with Guselkumab: A Machine Learning Analysis
Alen Zabotti¹, Sarah Ohrndorf², William Tillett³, Marlies Neuhold⁴, Michel van Speybroeck⁵, Elke Theander⁶, Christine Contré⁷, Mohamed Sharaf⁸, May Shawi⁹, Michelle Perate¹⁰, Alexa Kollmeier¹¹ and Pascal Richette¹², ¹Department of Medical and Biological Sciences, Rheumatology Unit, University of Udine, Udine, Italy, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁴Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁵Janssen Pharmaceutica, Beerse, Belgium, ⁶Janssen Cilag, Lund, Sweden, ⁷Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, ⁸Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, ⁹Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ¹⁰Janssen Scientific Affairs, LLC, Horsham, PA, ¹¹Janssen-Cilag, Research & Development, LLC, San Diego, CA, ¹²Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France
Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the interleukin-23p19 subunit, demonstrated joint and skin efficacy in patients with active psoriatic arthritis (PsA) in the…
Abstract Number: 2273 • ACR Convergence 2022
Waning Vaccine Response After Primary Vaccine Series: Results from the Covid19 Vaccine Response in Rheumatology Patients (COVER) Study
Amy Mudano¹, Gary Cutter², Ted Mikuls³, Geoffrey Thiele⁴, Mark Law⁴, Bart Hamilton⁴, Michael Zikry⁵, Kelly Y. Chun⁶, Monique Bastidas⁷, Michael George⁸, Lisa Williams⁹, Kevin Winthrop¹⁰, Mark Busch¹¹, Stanley Cohen¹², Roman Czubatyj¹³, Rajesh Kataria¹⁴, Reshma Khan¹⁵, Soha Mousa¹⁶, Jose Pando¹⁷, Elizabeth Perkins¹⁸, Shanmugapriya Reddy¹⁹, Delfin Santos²⁰, Joy Schechtman²¹, Frank Scott²², Sucharitha Shanmugam²³, Atul Singhal²⁴, John Tesser²⁵, John Tower²⁶, Swamy Venuturupalli²⁷, Sean Joseph Wollaston²⁸, Conrad Ziembinski²⁹ and Jeffrey Curtis³⁰, ¹Illumination Health, Hoover, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵LabCorp, Burlington, NC, ⁶Labcorp, Calabasas, CA, ⁷LabCorp, Northridge, CA, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Illumination Heath, Hoover, AL, ¹⁰Oregon Health & Science University, Portland, OR, ¹¹Family Arthritis Center-Jupiter, Jupiter, FL, ¹²Metroplex Clinical Research Center, Pittsburgh, PA, ¹³Arthritis Physicians LLC, Rochester Hills, MI, ¹⁴Southern Ohio, Wheelersburg, OH, ¹⁵Palm Beach Rheumatology and Wellness, Jupiter, FL, ¹⁶Arthritis and Rheumatology of Southwest Ohio, Liberty Township, OH, ¹⁷Rheumatology Consultants of DE, Lewes, DE, ¹⁸Rheumatology Care Center, Hoover, AL, ¹⁹Southwest Florida Rheumatology, Riverview, FL, ²⁰Rochester Rheumatology, Rochester Hills, MI, ²¹SunValley Arthritis Center, Peoria, AZ, ²²Arthritis Medical Center, Arroyo Grande, CA, ²³Rheumatology and Arthritis Care Center, Exton, PA, ²⁴Southwest Rheumatology Research, Mesquite, TX, ²⁵Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ²⁶Arthritis Physicians LLC, Rochester, MI, ²⁷Cedars-Sinai Medical Center, Los Angeles, CA, ²⁸Rheumatology Associates, North Hollywood, CA, ²⁹CZ Rheumatology, Coral Springs, FL, ³⁰Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Given possible increased risk of COVID-19 in patients with autoimmune conditions, there is a need to better understand the immunogenicity and safety of SARS-CoV-2…
Abstract Number: L07 • ACR Convergence 2021
Depletion of KLRG1+ T Cells in a First-in-human Clinical Trial of ABC008 in Inclusion Body Myositis (IBM)
Niti Goel¹, Dulce Soler-Ferran², Monette Coutreau², Jorge Escobar³, Kate Courtemanche², Merrilee Needham⁴ and Steven Greenberg⁵, ¹Abcuro, Inc.; Duke University, Durham, NC, ²Abcuro, Inc., Newton, MA, ³Abcuro, Inc., Hayward, CA, ⁴Perron Institute, Murdoch University, Perth, Australia, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Inclusion body myositis (IBM), a relentlessly progressive autoimmune skeletal muscle disease, has no effective available pharmacological therapy. A prominent feature of IBM on microscopy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].